2m 2m 2m 2m 2m 2m 2m
FRACTYL HEALTH (GUTS)
NASDAQ
$0.77-$0.02 (-2.75%)
Price as of Jun 03, 2026 7:01 PM EDT- $127.9MMarket Cap
- -59.50%1-Year Change
- BiotechnologyIndustry
FRACTYL HEALTH (GUTS)
$0.77-$0.02 (-2.75%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 0 -100.00% | 93,000 N/A | |
Cost of Revenue | 0 -100.00% | 50,000 N/A | |
Gross Profit | 43,000 0.00% | 43,000 N/A | |
Sales and Marketing Expense | 22.3M -3.56% | 23.1M N/A | |
Research and Development Expense | -74.5M +5.77% | -70.5M N/A | |
Depreciation and Amortization Expense | 1.1M +66.77% | 677,000 N/A | |
Total Operating Expenses | 96.8M +3.46% | 93.6M N/A | |
Operating Profit | -96.8M +3.51% | -93.5M N/A | |
Interest Income | 1.5M -62.86% | 4.1M N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 1.5M -62.86% | 4.1M N/A | |
Total Nonoperating Income and Expense | -44.1M -277.71% | 24.8M N/A | |
Income before Taxes | -141.0M +100.13% | -70.4M N/A | |
Income Taxes | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -141.0M +105.19% | -68.7M N/A | |
Net Income from Continuing Operations Applicable to Common | -141.0M +100.13% | -70.4M N/A | |
Basic EPS and Net Income | -1.86 +14.81% | -1.62 N/A | |
Diluted EPS and Net Income | -1.86 +14.81% | -1.62 N/A | |
Basic Weighted Average Shares | 75.8M +74.13% | 43.5M N/A | |
Diluted Weighted Average Shares | 75.8M +74.13% | 43.5M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 81.5M +20.86% | 67.5M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 81.5M +20.86% | 67.5M N/A | |
Total Current Assets | 87.6M +22.04% | 71.8M N/A | |
Accumulated Depreciation | 2.7M +70.78% | 1.6M N/A | |
Property and Plant and Equipment and Net | 2.4M -19.20% | 3.0M N/A | |
Total Long-Term Assets | 337,000 -49.40% | 666,000 N/A | |
Total Assets | 121.4M +12.33% | 108.1M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 18.3M -7.31% | 19.8M N/A | |
Total Long-Term Debt | 30.6M +1.41% | 30.2M N/A | |
Total Long-Term Liabilities | 663,000 -33.57% | 998,000 N/A | |
Total Liabilities | 111.9M +40.54% | 79.7M N/A | |
Retained Earnings | -556.3M +33.94% | -415.3M N/A | |
Total Stockholders Equity | 9.5M -66.73% | 28.4M N/A | |
Total Shares Outstanding | 153.4M +214.57% | 48.8M N/A | |
Cash Flow | |||
Cash from Operating Activities | -90.3M +37.86% | -65.5M N/A | |
Capital Expenditures | 557,000 -68.44% | 1.8M N/A | |
Cash from Investing Activities | -557,000 -68.44% | -1.8M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 105.0M +3.69% | 101.2M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | -122.85% N/A | N/A N/A | |
Return on Equity | -744.17% N/A | N/A N/A | |
Revenue Growth | -100.00% N/A | N/A N/A | |
Current Ratio | 4.78 N/A | N/A N/A | |
Cash Ratio | 4.45 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow